Medroxyprogesterone Acetate Articles
Pfizer fights back on HRT and cancer links highlighted by NYT
14 December 2009
Wyeth in US Senate ghostwriting probe
22 December 2008
$27M damages thrown out for Wyeth/Upjohn
21 July 2008
Wyeth's low-dose Prempro launched
7 July 2003
FDA approves Wyeth's low-dose Prempro
16 June 2003
FDA OKs Wyeth's low-dose Prempro
24 March 2003
Prempro may worsen cognition; new study
10 March 2003
US FDA tells women:
20 January 2003
Survey shows women not choosing most effective contraceptives
24 October 2001
W-A's Premarin is top US formulary drug
29 November 2000
Pharmacia gets FDA OK for once-monthly contraceptive
10 October 2000
Ligand gets $900K payment as lasofoxifene enters Ph III
27 September 2000
FDA approves Solvay's Prometrium
22 December 1998
HERS Casts Doubt On HRT Role In Heart Disease
20 August 1998
Pharmacia & Upjohn First Combined Results
26 February 1996
Zeneca's Arimidex Launched In First Market
25 September 1995
Upjohn suing AHP for infringment on Provera
22 May 1995
Sanofi Launches New HRT Approach In UK
8 May 1995
Depo-Provera Not Indicated In Breast Cancer
17 April 1995
Prempro Approved In USA
9 January 1995
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
DEPO PROVERA GOAHEAD FROM WHO
7 June 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
UPJOHN RESUBMITS DEPO-PROVERA IN USA
15 June 1992
FREEZES AT UPJOHN IN STRATEGY REVIEW
8 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
Showing 1-28 of 28 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
